AU3937693A - Methods and compositions for oral delivery of therapeutic agents - Google Patents

Methods and compositions for oral delivery of therapeutic agents

Info

Publication number
AU3937693A
AU3937693A AU39376/93A AU3937693A AU3937693A AU 3937693 A AU3937693 A AU 3937693A AU 39376/93 A AU39376/93 A AU 39376/93A AU 3937693 A AU3937693 A AU 3937693A AU 3937693 A AU3937693 A AU 3937693A
Authority
AU
Australia
Prior art keywords
compositions
methods
therapeutic agents
oral delivery
oral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU39376/93A
Inventor
Patricia A Gonnella
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Original Assignee
Brigham and Womens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham and Womens Hospital Inc filed Critical Brigham and Womens Hospital Inc
Publication of AU3937693A publication Critical patent/AU3937693A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU39376/93A 1992-04-10 1993-03-29 Methods and compositions for oral delivery of therapeutic agents Abandoned AU3937693A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86605492A 1992-04-10 1992-04-10
US866054 1992-04-10

Publications (1)

Publication Number Publication Date
AU3937693A true AU3937693A (en) 1993-11-18

Family

ID=25346833

Family Applications (1)

Application Number Title Priority Date Filing Date
AU39376/93A Abandoned AU3937693A (en) 1992-04-10 1993-03-29 Methods and compositions for oral delivery of therapeutic agents

Country Status (2)

Country Link
AU (1) AU3937693A (en)
WO (1) WO1993020834A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5587459A (en) * 1994-08-19 1996-12-24 Regents Of The University Of Minnesota Immunoconjugates comprising tyrosine kinase inhibitors
US5911995A (en) * 1994-08-19 1999-06-15 Regents Of The University Of Minnesota EGF-genistein conjugates for the treatment of cancer
DK1323346T3 (en) * 1995-01-17 2006-10-30 Brigham & Womens Hospital Receptor-specific transport of immunogens through the epithelium
US6030613A (en) * 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6086875A (en) * 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
US6485726B1 (en) 1995-01-17 2002-11-26 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
KR19990063632A (en) 1995-09-21 1999-07-26 디 헤이쓰, 산드라 우드 Transcytosis Mediators and Synergists for Drug Transport
US6495526B2 (en) * 1996-01-23 2002-12-17 Gpc Biotech, Inc. Inhibitors of cell-cycle progression and uses related thereto
US6261787B1 (en) * 1996-06-03 2001-07-17 Case Western Reserve University Bifunctional molecules for delivery of therapeutics
AU2002326070A1 (en) 2001-07-02 2003-01-21 Elan Corporation, Plc Peyers's patch and/or m-celle targeting ligands
US8188032B2 (en) 2003-10-10 2012-05-29 National Institutes Of Health (Nih) G-CSF transferrin fusion proteins

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5137877B1 (en) * 1990-05-14 1996-01-30 Bristol Myers Squibb Co Bifunctional linking compounds conjugates and methods for their production

Also Published As

Publication number Publication date
WO1993020834A1 (en) 1993-10-28

Similar Documents

Publication Publication Date Title
ZA968907B (en) Compositions and methods for buccal delivery of pharmaceutical agents
AU4534593A (en) Compositions and methods for enhanced drug delivery
ZA942804B (en) Oral drug delivery compositions and methods
ZA964735B (en) Compositions and methods for topical administration of pharmaceutically active agents
HUP9902105A3 (en) Pharmaceutical angiostatic dipeptide compositions and methods of use thereof
AU3201093A (en) Dental composition and method
AU5178296A (en) Induction of e-selectin for targetting therapeutic agents
AUPO727097A0 (en) Method of treatment of hepatoma and pharmaceutical compositions for use therein
HUP0101017A3 (en) Compositions and methods for systemic delivery of oral vaccines and therapeutic agents
AU678971B2 (en) Compositions and methods for vaccination against coronaviruses
ZA936964B (en) Pharmaceutical compositions containing derivatives of nomegestrol and their process of manufacture
IL118636A (en) Oral pharmaceutical compositions of S(+)-etodolac
AU2180097A (en) Composition for prevention and treatment of periodontal diseases
HUP9900186A3 (en) Use of lamellarin alkaloids in therapy and pharmaceutical compositions containing them
AU3937693A (en) Methods and compositions for oral delivery of therapeutic agents
AU3461095A (en) Compositions and methods for delivery of polypeptides
HUP9900147A2 (en) Therapeutic agents and pharmaceutical compositions for treatment of autoimmune diseases
IL105135A (en) Carbapenems their preparation their use and pharmaceutical compositions containing them
AU2081492A (en) Method of controlling dental tartar and compositions for use therein
AU1432292A (en) Drug delivery composition and method of using the same
GB2294637B (en) Therapeutic compositions and methods of use
AU2587195A (en) Growth hormone therapy and related methods and pharmaceutical compositions
AU3862293A (en) Hydrophillic creams for delivery of therapeutic agents
AU4663493A (en) Method for delivery of cytotoxic agents and components thereof
AU4491697A (en) Compositions of therapeutic agents suitable for oral administration